Accord Healthcare C/O Qestmed (pty) Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Accord Healthcare C/O Qestmed (pty) Pharmaceutical Import Records from India — 2 Products, $209.9K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare C/O Qestmed (pty) — Pharmaceutical Importer Profile (2026) | 2 Products, $209.9K Trade | TransData Nexus

Accord Healthcare C/O Qestmed (pty)

Pharmaceutical Importer · South Africa · Advanced Oncology Focus · $209.9K Total Trade · DGFT Verified

Accord Healthcare C/O Qestmed (pty) is a pharmaceutical importer based in South Africa with a total trade value of $209.9K across 2 products in 1 therapeutic categories. Based on 5 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare C/O Qestmed (pty) sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare C/O Qestmed (pty) — Import Portfolio & Supplier Network

Accord Healthcare C/O Qestmed (pty) import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare C/O Qestmed (pty)?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$81.2K	7	100.0%

Accord Healthcare C/O Qestmed (pty) sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharma drugs & medi: pecaset 500 MG	$39.5K	3
Pharma drugs & medi: rubexet 50MG (2MG/ML 25ML)	$13.9K	1
Pharma drugs & medi: actamasin exemestane25mg 3x10t ima(ac-sa	$12.9K	1
Pharma drugs & medi: capexa capecitabine150 MG 6x10t(acc-sa	$10.6K	1
Pharma drugs & medi:bonrix ibandronic acid2mg/2ML 1v(acc-sa)	$4.3K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Letrozole	Advanced Oncology	$150.0K	3	0.5%	14
2	Busulfan	Advanced Oncology	$59.9K	2	1.2%	13

Accord Healthcare C/O Qestmed (pty) imports 2 pharmaceutical products across 1 categories into South Africa totaling $209.9K.

Accord Healthcare C/O Qestmed (pty) — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare C/O Qestmed (Pty) Ltd. is a South African pharmaceutical importer and distributor specializing in oncology medications. The company operates under the auspices of Qestmed, a wholly owned private South African healthcare entity with over 35 years of experience in supplying healthcare goods and services to both public and private sectors nationally. (qestmed.co.za) Qestmed is registered with the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC), holding licenses as a pharmaceutical and medical device wholesaler and distributor. (qestmed.co.za)

Accord Healthcare, the parent company, is a multinational pharmaceutical firm that develops, manufactures, and distributes generic, biosimilar, and added-value medicines in over 85 countries worldwide. Their South African operations are based in Woodmead, Gauteng, where they offer an extensive portfolio encompassing oncology, cardiology, urology, respiratory, central nervous system (CNS), and hospital products. (accordhealth.co.za) Accord Healthcare's mission is to improve access to essential and affordable medicines, aligning with their vision to "Make it Better." (accordhealth.co.za)

2Distribution Network

Qestmed's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across South Africa. The company operates multiple warehouses and logistics centers, including facilities in Johannesburg, Durban, Cape Town, and Port Elizabeth. These locations enable Qestmed to provide comprehensive coverage, serving both public and private healthcare sectors nationwide. (qestmed.co.za) The company's logistics capabilities are enhanced by a validated temperature-controlled in-house fleet, ensuring the integrity of sensitive products, particularly in the oncology division. (qestmed.co.za)

3Industry Role

Accord Healthcare C/O Qestmed (Pty) Ltd. functions as a pharmaceutical importer and distributor within South Africa's healthcare supply chain. By importing finished pharmaceutical formulations from international suppliers, including India, and distributing them through its extensive network, the company plays a pivotal role in ensuring the availability of essential medicines, particularly in the oncology sector. This position allows Accord Healthcare to address the specific needs of the South African market, contributing to the overall efficiency and effectiveness of the country's healthcare delivery system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare C/O Qestmed (pty)

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare's sourcing strategy exhibits a high degree of concentration, with a total import value of $210,000 USD from India across five shipments, all sourced from a single supplier, Intas Pharmaceuticals Limited. This single-source dependency may present risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent volume and frequency of shipments suggest a stable and reliable relationship between Accord Healthcare and Intas Pharmaceuticals. The focus on oncology medications, specifically Letrozole and Busulfan, indicates a strategic choice to concentrate on high-demand therapeutic areas, potentially leveraging favorable pricing and supply terms with the supplier.

2Supply Chain Resilience

The resilience of Accord Healthcare's supply chain is closely tied to its exclusive reliance on Intas Pharmaceuticals Limited for oncology medications. While this concentrated sourcing strategy may streamline operations and strengthen supplier relationships, it also exposes the company to risks associated with supply chain disruptions, such as production delays or regulatory changes affecting the supplier. The absence of backup suppliers and limited formulation diversity within the oncology category may further exacerbate these risks. To enhance supply chain resilience, it would be prudent for Accord Healthcare to consider diversifying its supplier base and expanding its product portfolio to mitigate potential vulnerabilities.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary regulatory body overseeing the importation, registration, and distribution of medicines in South Africa. SAHPRA operates under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), which provides the legislative framework for regulating health products in the country. This act encompasses the monitoring, evaluation, regulation, investigation, inspection, registration, and control of medicines, scheduled substances, medical devices, radiation control, clinical trials, and related matters in the public interest. (sahpra.org.za)

2Import Licensing & GMP

To import medicines into South Africa, companies must obtain a license from SAHPRA, which authorizes them to import and distribute specific categories of health products. Additionally, importers must be registered with the South African Pharmacy Council (SAPC) as a manufacturing or wholesale pharmacy and must appoint a dedicated responsible pharmacist to oversee operations. Compliance with Good Manufacturing Practices (GMP) is mandatory, and SAHPRA requires adherence to guidelines related to GMP and Good Distribution Practices (GDP) to ensure the quality, safety, and efficacy of imported medicines.

Quality & Labeling

Accord Healthcare C/O Qestmed (pty) — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare's focus on importing oncology medications, specifically Letrozole and Busulfan, aligns with the high demand for cancer treatments in South Africa. The strategic emphasis on these products suggests a targeted approach to address critical therapeutic needs within the oncology sector. Market demand for effective and affordable cancer treatments drives the importation of these specific formulations, positioning Accord Healthcare as a key player in providing essential oncology medications to the South African market.

2Sourcing Profile

Accord Healthcare's sourcing strategy is centered on importing generic oncology formulations from India, particularly from Intas Pharmaceuticals Limited. This approach leverages India's established reputation for producing high-quality generic medicines at competitive prices. The focus on finished pharmaceutical formulations, rather than active pharmaceutical ingredients (APIs) or bulk drugs, indicates a preference for ready-to-market products that can be directly distributed to healthcare providers and patients.

3Market Positioning

By importing and distributing oncology medications, Accord Healthcare serves the hospital and specialty pharmacy segments of the South African market. The company's product mix positions it to meet the needs of healthcare providers involved in cancer care, ensuring the availability of essential treatments for patients. This strategic positioning allows Accord Healthcare to contribute significantly to the oncology therapeutic area within the South African healthcare system.

Seller's Guide — How to Become a Supplier to Accord Healthcare C/O Qestmed (pty)

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the South African market by offering a broader range of oncology formulations or by diversifying into other therapeutic areas. Accord Healthcare's current sourcing pattern, with a heavy reliance on a single supplier for oncology products, presents potential gaps that new suppliers can fill. By providing alternative sources for high-demand medications, new entrants can enhance supply chain resilience and meet the evolving needs of the South African healthcare system.

2Requirements & Qualifications

Indian exporters seeking to supply Accord Healthcare and the South African market must obtain a license from SAHPRA, authorizing them to import and distribute specific categories of health products. Additionally, they must be registered with the South African Pharmacy Council (SAPC) as a manufacturing or wholesale pharmacy and appoint a dedicated responsible pharmacist to oversee operations. Compliance with Good Manufacturing Practices (GMP) and adherence to SAHPRA's guidelines related to GMP and Good Distribution Practices (GDP) are mandatory to ensure the quality, safety, and efficacy of imported medicines.

How to Approach

Frequently Asked Questions — Accord Healthcare C/O Qestmed (pty)

What products does Accord Healthcare C/O Qestmed (pty) import from India?

Accord Healthcare C/O Qestmed (pty) imports 2 pharmaceutical products across 1 categories. Top imports: Letrozole ($150.0K), Busulfan ($59.9K).

Who supplies pharmaceuticals to Accord Healthcare C/O Qestmed (pty) from India?

Accord Healthcare C/O Qestmed (pty) sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $81.2K).

What is Accord Healthcare C/O Qestmed (pty)'s total pharmaceutical import value?

Accord Healthcare C/O Qestmed (pty)'s total pharmaceutical import value from India is $209.9K, based on 5 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare C/O Qestmed (pty) focus on?

Accord Healthcare C/O Qestmed (pty) imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Accord Healthcare C/O Qestmed (pty) Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.